RE: EUBCL acceptance26 Sep 2018 21:37
Anything that contributes towards funding and delays a potential cash call sounds good to me.
This certainly gets me juiced up Bidnolid:
‘Under the terms of the collaboration agreement with the Company, MedImmune has the right at any time during the collaboration project, and 3 months following its conclusion, to give notice that it wishes to negotiate the terms on which N4 would grant it an exclusive licence to utilise the results of the evaluation.’